Ascletis Pharma (HKSE:01672) EPS (Diluted) : HK$-0.15 (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma EPS (Diluted)?

Ascletis Pharma's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$-0.13. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.15.

Ascletis Pharma's EPS (Basic) for the six months ended in Dec. 2023 was HK$-0.13. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.15.

Ascletis Pharma's EPS without NRI for the six months ended in Dec. 2023 was HK$-0.20. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.22.

During the past 3 years, the average EPS without NRIGrowth Rate was -7.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Ascletis Pharma's highest 3-Year average EPS without NRI Growth Rate was -7.00% per year. The lowest was -90.60% per year. And the median was -30.65% per year.

Ascletis Pharma EPS (Diluted) Historical Data

The historical data trend for Ascletis Pharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma EPS (Diluted) Chart

Ascletis Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-0.10

-0.24

-0.22

-0.32

-0.15

Ascletis Pharma Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial										-0.10	-0.10	-0.23	-0.02	-0.13

Competitive Comparison of Ascletis Pharma's EPS (Diluted)

For the Biotechnology subindustry, Ascletis Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascletis Pharma's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's PE Ratio falls into.

Ascletis Pharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Ascletis Pharma's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-158.286	-	0)	/	1074.103
	=	-0.15

Ascletis Pharma's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-140.174	-	0)	/	1061.283
	=	-0.13

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.15

Ascletis Pharma (HKSE:01672) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Ascletis Pharma EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascletis Pharma (HKSE:01672) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

ASCLF:USA

Address

198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200

Website

https://www.ascletis.com

Ascletis Pharma Inc is an investment holding company engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. ritonavir tablets, GANOVO, and ASCLEVIR. Geographically, it operates in Mainland China and other countries.

Executives

Jjw12 Limited
Lakemont Holding Llc
Wu Jinzi Jason	2101 Beneficial owner
Wu Judy Hejingdao	2101 Beneficial owner
Jjw11 Limited
C-bridge Capital Gp, Ltd.	2201 Interest of corporation controlled by you
Fu Wei	2201 Interest of corporation controlled by you
Tf Capital Ii Ltd.	2201 Interest of corporation controlled by you
Tf Capital, Ltd.	2201 Interest of corporation controlled by you
Kang Hua Investment Company Limited	2201 Interest of corporation controlled by you
Yang Dan	2201 Interest of corporation controlled by you

Ascletis Pharma (HKSE:01672) Headlines

No Headlines